We use data from seven low and middle income countries with diverse drug procurement
systems to assess the effect of centralized procurement on drug prices, and provide a …

High administrative costs in US health care have provoked concern among policymakers
over potential waste, but many of these costs are generated by managed care policies that …

Entry represents a fundamental threat to cartels engaged in price fixing. We study the extent
and effect of this behavior in the largest price fixing case in US history, which involves …

This paper examines the effects of privatizing social health insurance in the United States.
We study this question in the context of the Medicaid program, the largest health insurer in …

We study cartels that operated in the US generic drug industry, leveraging quarterly
Medicaid data for the period 2011–2018 and a difference-in-differences approach …

The US pharmaceutical pricing is out of control [1]. One analysis of 145 drugs used for 373
cancer indications revealed an average cost of nearly $300 000/year. For many of these …

The paper summarizes the evidence on regulatory and competition policy weaknesses in
dealing with healthcare market failures associated with the entry of private equity (PE) …

More than 90% of prescriptions dispensed in the United States each year are for off-patent
drugs. Yet the bulk of scholarship on prescription drug policy focuses on patented drugs …

The household's price elasticity of demand is a key input to many economic models'
construction of markups and the assessment of consumer surplus. We measure the price …

A firm's residual demand elasticity takes into account both the household's demand elasticity
and the equilibrium response of competitors, and therefore measures its market power. We …